Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 14, 2025

Biased Signaling in Psychedelic Action.

View Full Paper
Ask AI
Bookmark
Share

Authors

DWDaniel WackerJMJohn D. McCorvy

Discussion

Loading...

Member takes

Overview

This review highlights biased agonist compounds influencing 5-HT2A receptor signaling in psychiatric disorders, suggesting paths for new therapies.

Key Points

  • Psychedelics show potential for treating psychiatric disorders through specific receptor activation.
  • 5-HT2A receptor activation is crucial for therapeutic effects, yet signaling pathways remain unclear.
  • Research on biased agonists aims to separate therapeutic effects from adverse reactions, promoting safety.
  • Insights into the design of novel compounds may enhance the efficacy of psychedelic-based pharmacotherapies.

Cite This Study

Wacker et al. (2025) studied this question.

synapsesocial.com/papers/689fc6912abb084d53ed25dahttps://doi.org/10.1146/annurev-pharmtox-062124-012545
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Increased 5-HT<sub>2A</sub>receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics2024 · 1 citations
  2. 25-HT2A receptor and psychedelics: a trip through the mechanisms of action and therapeutic potential in mental disorders2026
  3. 3Pathway-selective signaling of serotonergic psychedelics at 5-HT receptors: Implications for psychoactivity, safety, and therapeutic potential2026 · 4 citations
  4. 4A dual-receptor model of serotonergic psychedelics2024 · 3 citations
  5. 5Target-Based Drug Discovery: Discovery and Synthesis of G-Protein Biased Agonists Towards the 5-Hydroxytryptamine2A Receptor2025